Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.

about

Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.

P2860

Q50113702-7D396FE8-547B-4B61-B020-3E8488A2A78C

P2860

Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.

Item

http://www.wikidata.org/entity/Q41093141

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.

@en

type

Item

label

Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.

@en

prefLabel

Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.

@en

P1476

Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.

@en

P2093

Alex Armstrong

http://www.w3.org/2001/XMLSchema#string

Hong-Fei Wu

http://www.w3.org/2001/XMLSchema#string

Jia-Geng Zhu

http://www.w3.org/2001/XMLSchema#string

Jian-Zhong Lin

http://www.w3.org/2001/XMLSchema#string

Ming Zheng

http://www.w3.org/2001/XMLSchema#string

Wei De

http://www.w3.org/2001/XMLSchema#string

Wei-Zhang Xu

http://www.w3.org/2001/XMLSchema#string

Zeng-Jun Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies

AXL kinase as a novel target for cancer therapy

The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma.

Cancer statistics, 2013

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

Androgen receptor splice variants determine taxane sensitivity in prostate cancer.

Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer

Phosphoproteomic analysis of Her2/neu signaling and inhibition.

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.

P304

41064-41077

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.17026

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28455956

http://www.w3.org/2001/XMLSchema#string

P932

5522277

http://www.w3.org/2001/XMLSchema#string

Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.

about

P2860

P2860

Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932